KRAS and neoplasm: The fact that DDR1 expression level is not restricted to any specific CMS subclass and that its tumor-promoting function is KRAS mutation-independent suggests that DDR1 inhibitors could be active in all CRC subtypes, including CMS3 tumors for which the therapeutic options are limited.